Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 31 results.
User Information
Export Records
  1. 1.   Identification of pyrrolo[3',4':3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas
  2. Barreca, Marilia; Spanò, Virginia; Rocca, Roberta; Bivacqua, Roberta; Gualtieri, Gianmarco; Raimondi, Maria Valeria; Gaudio, Eugenio; Bortolozzi, Roberta; Manfreda, Lorenzo; Bai,Ruoli; Montalbano, Alessandra; Alcaro, Stefano; Hamel,Ernest; Bertoni, Francesco; Viola, Giampietro; Barraja, Paola
  3. European Journal of Medicinal Chemistry. 2023, Apr 12; 254: 115372.
  1. 2.   Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
  2. Brudno, Jennifer N; Lam, Norris; Vanasse, Danielle; Shen, Yueh-Wei; Rose, Jeremy J; Rossi, John; Xue, Allen; Bot, Adrian; Scholler, Nathalie; Mikkilineni, Lekha; Roschewski, Mark; Dean, Robert; Cachau,Raul; Youkharibache, Philippe; Patel, Rashmika; Hansen, Brenna; Stroncek, David F; Rosenberg, Steven A; Gress, Ronald E; Kochenderfer, James N
  3. Nature medicine. 2020, Jan 20;
  1. 3.   Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Chen, A.; Ji, J. P.; Zhang, Y. P.; Reid, J. M.; Ames, M.; Jia, L.; Weil, M.; Speranza, G.; Murgo, A. J.; Kinders, R.; Wang, L. H.; Parchment, R. E.; Carter, J.; Stotler, H.; Rubinstein, L.; Hollingshead, M.; Melillo, G.; Pommier, Y.; Bonner, W.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Cancer Research. 2011, Sep; 71(17): 5626-5634.
  1. 4.   The statistics of phase 0 trials
  2. Rubinstein, L. V.; Steinberg, S. M.; Kummar, S.; Kinders, R.; Parchment, R. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Statistics in Medicine. 2010, May; 29(10): 1072-1076.
  1. 5.   Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer
  2. Senchenko, V. N.; Anedchenko, E. A.; Kondratieva, T. T.; Krasnov, G. S.; Dmitriev, A. A.; Zabarovska, V. I.; Pavlova, T. V.; Kashuba, V. I.; Lerman, M. I.; Zabarovsky, E. R.
  3. Bmc Cancer. 2010, Mar; 10: 13.
  1. 6.   HYAL1 and HYAL2 Inhibit Tumour Growth In Vivo but Not In Vitro
  2. Wang, F. L.; Grigorieva, E. V.; Li, J. F.; Senchenko, V. N.; Pavlova, T. V.; Anedchenko, E. A.; Kudryavtseva, A. V.; Tsimanis, A.; Angeloni, D.; Lerman, M. I.; Kashuba, V. I.; Klein, G.; Zabarovsky, E. R.
  3. Plos One. 2008, Aug; 3(8): 8.
  1. 7.   2 '-deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: A novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase
  2. Byun, H. M.; Choi, S. H.; Laird, P. W.; Trinh, B.; Siddiqui, M. A.; Marquez, V. E.; Yang, A. S.
  3. Cancer Letters. 2008 266(2): 238-248.
  1. 8.   Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
  2. Cao, L.; Yu, Y. K.; Darko, I.; Currier, D.; Mayeenuddin, L. H.; Wan, X. L.; Khanna, C.; Helman, L. J.
  3. Cancer Research. 2008 68(19): 8039-8048.
  1. 9.   Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan
  2. Yang, X. H. R.; Goldstein, A. M.; Chen, C. J.; Rabkin, C. S.; Chen, J. Y.; Cheng, Y. J.; Hsu, W. L.; Sun, B.; Diehl, S. R.; Liu, M. Y.; Walters, M.; Shao, W.; Ortiz-Conde, B. A.; Whitby, D.; Elmore, S. H.; Gulley, M. L.; Hildesheim, A.
  3. International Journal of Cancer. 2006, MAR 1; 118(3): 780-784.
  1. 10.   The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma
  2. Herranz, M.; Martin-Caballero, J.; Fraga, M. F.; Ruiz-Cabello, J.; Flores, J. M.; Desco, M.; Marquez, V.; Esteller, M.
  3. Blood. 2006, FEB 1; 107(3): 1174-1177.
  1. 11.   Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment
  2. Waalkes, M. P.; Liu, J.; Ward, J. M.; Powell, D. A.; Diwan, B. A.
  3. Cancer Research. 2006, FEB 1; 66(3): 1337-1345.
  1. 12.   Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma
  2. Kovacic, M. B.; Martin, M.; Gao, X. J.; Fuksenko, T.; Chen, C. J.; Cheng, Y. J.; Chen, J. Y.; Apple, R.; Hildesheim, A.; Carrington, M.
  3. Cancer Epidemiology Biomarkers & Prevention. 2005, NOV; 14(11, Part 1): 2673-2677.
  1. 13.   Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies - Distinct HLA-A, -B, -Cw,-DRB1 and -DQA1 allelic profiles and motifs define clinicopothologic groups in Caucasians
  2. O'Hanlon, T. P.; Carrick, D. M.; Arnett, F. C.; Reveille, J. D.; Carrington, M.; Gao, X. J.; Oddis, C. V.; Morel, P. A.; Malley, J. D.; Malley, K.; Dreyfuss, J.; Shamim, E. A.; Rider, L. G.; Chanock, S. J.; Foster, C. B.; Bunch, T.; Plotz, P. H.; Love, L. A.; Miller, F. W.
  3. Medicine. 2005, NOV; 84(6): 338-349.
  1. 14.   Expression of hypoxia-inducible carbonic anhydrases in brain tumors
  2. Proescholdt, M. A.; Mayer, C.; Kubitza, M.; Schubert, T.; Liao, S. Y.; Stanbridge, E. J.; Ivanov, S.; Oldfield, E. H.; Brawanski, A.; Merrill, M. J.
  3. Neuro-Oncology. 2005, OCT; 7(4): 465-475.
  1. 15.   Limiting dilution analysis of interleukin-2 producing helper T-cell frequencies as a tool in allogeneic hematopoietic cell transplantation
  2. Petersen, S. L.; Sidorov, I. A.; Russell, C. A.; Dickmeiss, E.; Vindelov, L. L.
  3. Transplantation. 2005, SEP 15; 80(5): 573-581.
  1. 16.   Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme
  2. Krauss, J.; Arndt, M. A. E.; Vu, B. K.; Newton, D. L.; Rybak, S. M.
  3. British Journal of Haematology. 2005, MAR; 128(5): 602-609.
  1. 17.   Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia
  2. Lemaire, M.; Momparler, L. F.; Bernstein, M. L.; Marquez, V. E.; Momparler, R. L.
  3. Anti-Cancer Drugs. 2005, MAR; 16(3): 301-308.
  1. 18.   Cytotoxicity of RH1: NAD(P)H : quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction
  2. Tudor, G.; Alley, M.; Nelson, C. M.; Huang, R. L.; Covell, D. G.; Gutierrez, P.; Sausville, E. A.
  3. Anti-Cancer Drugs. 2005 16(4): 381-391.
  1. 19.   IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8(+) T cells
  2. Salcedo, R.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Hixon, J. A.; Hahn, C.; Shafer-Weaver, K.; Malyguine, A.; Kastelein, R.; Wigginton, J. M.
  3. Journal of Immunology. 2004, DEC 15; 173(12): 7170-7182.
  1. 20.   Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen
  2. Neelapu, S. S.; Baskar, S.; Gause, B. L.; Kobrin, C. B.; Watson, T. M.; Frye, A. R.; Pennington, R.; Harvey, L.; Jaffe, E. S.; Robb, R. J.; Popescu, M. C.; Kwak, L. W.
  3. Clinical Cancer Research. 2004, DEC 15; 10(24): 8309-8317.
  1. 21.   Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C
  2. Li, F.; Wang, F.; Haraldson, K.; Protopopov, A.; Duh, F. M.; Geil, L.; Kuzmin, I.; Minna, J. D.; Stanbridge, E.; Braga, E.; Kashuba, V. I.; Klein, G.; Lerman, M. I.; Zabarovsky, E. R.
  3. Cancer Research. 2004, SEP 15; 64(18): 6438-6443.
  1. 22.   Getting back on track, or what to do when apoptosis is de-railed - Recoupling oncogenes to the apoptotic machinery
  2. Fearnhead, H. O.
  3. Cancer Biology & Therapy. 2004 3(1): 21-28.
  1. 23.   Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee
  2. Shappell, S. B.; Thomas, G. V.; Roberts, R. L.; Herbert, R.; Ittmann, M. M.; Rubin, M. A.; Humphrey, P. A.; Sundberg, J. P.; Rozengurt, N.; Barrios, R.; Ward, J. M.; Cardiff, R. D.
  3. Cancer Research. 2004 64(6): 2270-2305.
  1. 24.   Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells
  2. Hodge, D. R.; Xiao, W. H.; Wang, L. H.; Li, D. P.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2004 3(2): 188-194.
  1. 25.   RBSP3 (HYA22) is a tumor suppressor gene implicated in major epithelial malignancies
  2. Kashuba, V. I.; Li, J. F.; Wang, F. L.; Senchenko, V. N.; Protopopov, A.; Malyukova, A.; Kutsenko, A. S.; Kadyrova, E.; Zabarovska, V. I.; Muravenko, O. V.; Zelenin, A. V.; Kisselev, L. L.; Kuzmin, I.; Minna, J. D.; Winberg, G.; Ernberg, I.; Braga, E.; Lerman, M. I.; Klein, G.; Zabarovsky, E. R.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2004 101(14): 4906-4911.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel